Jiangxi Baishen Pharmaceutical Co., Ltd.
Jiangxi Baishen Pharmaceutical Co., Ltd. was founded in 2002 and is located in Yuanzhou Pharmaceutical Industrial Park, Yichun City. It is a modern pharmaceutical enterprise integrating the research and development, production and sales of patent medicines, traditional Chinese medicine formula granules, and Chinese herbal medicines. It has Jiangxi Baishen Changnuo Pharmaceutical Co., Ltd. and Jiangxi Baishen Pharmaceutical Co., Ltd. are two wholly-owned subsidiaries. The company has 1 national engineering research center, 1 academician workstation, 2 provincial enterprise technology centers, and 1 provincial laboratory. It has carried out drug research and development cooperation with well-known domestic drug research and development institutions and more than 10 listed pharmaceutical companies, and has strong R&D strength and technical level. During the 12th Five-Year Plan period, the company twice undertakes major scientific research tasks for the national "major new drug creation" science and technology, and has been successfully completed. The company has two major production bases in Yichun and Fuzhou, covering an area of 517 mu, with a factory area of more than 80,000 square meters, and has numerous production equipment and more than 10 modern production lines. The company adheres to the concept of quality first and strictly follows the requirements of GMP and GSP to produce and operate high-quality medicines. The company has more than 10 pharmaceutical dosage forms and health foods, with more than 600 production approval documents, covering more than 8 major series and more than 600 varieties, forming a complete group of traditional Chinese medicine series products. Baishen brand products are deeply loved by customers and consumers for their advantages in quality, efficacy, brand and other advantages. The company has a professional marketing team that adheres to customer-centricity and implements three major driving forces for customers, including policies, emotions and goals, forming a nationwide marketing network, with sales revenue growing year by year.
Jiangxi Baishen Pharmaceutical Co., Ltd.
Jiangxi Baishen Pharmaceutical Co., Ltd. was founded in 2002 and is located in Yuanzhou Pharmaceutical Industrial Park, Yichun City. It is a modern pharmaceutical enterprise integrating the research and development, production and sales of patent medicines, traditional Chinese medicine formula granules, and Chinese herbal medicines. It has Jiangxi Baishen Changnuo Pharmaceutical Co., Ltd. and Jiangxi Baishen Pharmaceutical Co., Ltd. are two wholly-owned subsidiaries. The company has 1 national engineering research center, 1 academician workstation, 2 provincial enterprise technology centers, and 1 provincial laboratory. It has carried out drug research and development cooperation with well-known domestic drug research and development institutions and more than 10 listed pharmaceutical companies, and has strong R&D strength and technical level. During the 12th Five-Year Plan period, the company twice undertakes major scientific research tasks for the national "major new drug creation" science and technology, and has been successfully completed. The company has two major production bases in Yichun and Fuzhou, covering an area of 517 mu, with a factory area of more than 80,000 square meters, and has numerous production equipment and more than 10 modern production lines. The company adheres to the concept of quality first and strictly follows the requirements of GMP and GSP to produce and operate high-quality medicines. The company has more than 10 pharmaceutical dosage forms and health foods, with more than 600 production approval documents, covering more than 8 major series and more than 600 varieties, forming a complete group of traditional Chinese medicine series products. Baishen brand products are deeply loved by customers and consumers for their advantages in quality, efficacy, brand and other advantages. The company has a professional marketing team that adheres to customer-centricity and implements three major driving forces for customers, including policies, emotions and goals, forming a nationwide marketing network, with sales revenue growing year by year.
Hainan Calabash Kids Pharmaceutical Group Co., Ltd.
Huluwa Pharmaceutical Group takes "Healthy Chinese Babies" as its corporate mission to protect the healthy growth of Chinese children and is committed to building a national brand of Chinese children's medicine. Huluwa Pharmaceutical Group is a group enterprise with Haikou as its headquarters. It was reorganized in 2008 and was listed on the main board of the Shanghai Stock Exchange in July 2020 (stock abbreviation: Huluwa, stock code: 605199). After more than ten years of development, the group has worked hard in the field of pediatric medicine, focusing on building the entire life cycle of children and the full category of health and product industry chain, firmly following the development of pediatric medicine, and has now become one of the leading enterprises in the field of professional pediatric medicine. , and was selected as the vice chairman of the Pediatrics Branch of the Chinese Society of Traditional Chinese Medicine and the vice president of the Pediatrics Branch of the Chinese Society of Ethnic Medicine. The group focuses on scientific and technological innovation, lean production, brand building and professional services. It has now built two major production bases in Haikou, Hainan and Nanning, Guangxi. The Haikou Mei'an Children's Medicine Intelligent Manufacturing Base will be put into production this year; a total of 34 production and sales are Children's medicines, the main products include pediatric lung heat cough and asthma granules, enteroyanning series, compound lysine granules, etc., with about 120 products under development; the sales network covers more than 2,300 counties and cities in all provinces and regions. In addition, the group has successively established academician workstations, postdoctoral research workstations, Hainan Traditional Chinese Medicine Preparation Engineering Technology Research Center, and the Joint Development Laboratory of Southern Pharmaceuticals, and jointly built an international innovation platform for high-end children's preparations research and development with well-known domestic R&D companies. At the same time, after going public, the group has integrated various management work into ESG governance and actively assumed social responsibilities. Every year, through the children's committees of various industry societies and associations, it invested a lot of resources to ensure the safe use of medicine for children. We launched a public welfare project such as the "Spring Bree Class" that donated money to girls to enroll, and we have donated and expressed condolences to Haikou Social Welfare Institute for 7 consecutive years. Huluwa Pharmaceutical Group insists on party building to lead the high-quality development of the enterprise, relying on the historical opportunity of the construction of Hainan Free Trade Port, continues to deepen changes with the new development concept, constantly improve product quality and craftsmanship with the spirit of craftsmanship, and wins market recognition with professional services. We will strive to become the guardian of China's children's health field, help China move from a major pharmaceutical manufacturing country to a strong pharmaceutical innovation country, and contribute the strength of the Huluwa in the new journey of promoting the great rejuvenation of the Chinese nation with Chinese-style modernization!
Hainan Calabash Kids Pharmaceutical Group Co., Ltd.
Huluwa Pharmaceutical Group takes "Healthy Chinese Babies" as its corporate mission to protect the healthy growth of Chinese children and is committed to building a national brand of Chinese children's medicine. Huluwa Pharmaceutical Group is a group enterprise with Haikou as its headquarters. It was reorganized in 2008 and was listed on the main board of the Shanghai Stock Exchange in July 2020 (stock abbreviation: Huluwa, stock code: 605199). After more than ten years of development, the group has worked hard in the field of pediatric medicine, focusing on building the entire life cycle of children and the full category of health and product industry chain, firmly following the development of pediatric medicine, and has now become one of the leading enterprises in the field of professional pediatric medicine. , and was selected as the vice chairman of the Pediatrics Branch of the Chinese Society of Traditional Chinese Medicine and the vice president of the Pediatrics Branch of the Chinese Society of Ethnic Medicine. The group focuses on scientific and technological innovation, lean production, brand building and professional services. It has now built two major production bases in Haikou, Hainan and Nanning, Guangxi. The Haikou Mei'an Children's Medicine Intelligent Manufacturing Base will be put into production this year; a total of 34 production and sales are Children's medicines, the main products include pediatric lung heat cough and asthma granules, enteroyanning series, compound lysine granules, etc., with about 120 products under development; the sales network covers more than 2,300 counties and cities in all provinces and regions. In addition, the group has successively established academician workstations, postdoctoral research workstations, Hainan Traditional Chinese Medicine Preparation Engineering Technology Research Center, and the Joint Development Laboratory of Southern Pharmaceuticals, and jointly built an international innovation platform for high-end children's preparations research and development with well-known domestic R&D companies. At the same time, after going public, the group has integrated various management work into ESG governance and actively assumed social responsibilities. Every year, through the children's committees of various industry societies and associations, it invested a lot of resources to ensure the safe use of medicine for children. We launched a public welfare project such as the "Spring Bree Class" that donated money to girls to enroll, and we have donated and expressed condolences to Haikou Social Welfare Institute for 7 consecutive years. Huluwa Pharmaceutical Group insists on party building to lead the high-quality development of the enterprise, relying on the historical opportunity of the construction of Hainan Free Trade Port, continues to deepen changes with the new development concept, constantly improve product quality and craftsmanship with the spirit of craftsmanship, and wins market recognition with professional services. We will strive to become the guardian of China's children's health field, help China move from a major pharmaceutical manufacturing country to a strong pharmaceutical innovation country, and contribute the strength of the Huluwa in the new journey of promoting the great rejuvenation of the Chinese nation with Chinese-style modernization!
Shenwei Pharmaceutical Group Co., Ltd.
Shenwei Pharmaceutical Group is a large comprehensive enterprise group with the new Chinese medicine industry as its main business, and is listed on the main board of the Hong Kong Stock Exchange. Its main business covers Chinese medicinal materials cultivation, Chinese medicine preparations, Chinese medicine formula granules, Chinese herbal medicines, health products, and biopharmaceuticals. The upstream, midstream and downstream industrial chains have achieved full coverage of the new Chinese medicine industry from the field to the terminal, and are one of the large pharmaceutical enterprise groups with a relatively complete layout in the big health industry. Shenwei Pharmaceutical has formed special products such as modern Chinese medicine injections, modern Chinese medicine soft capsules, modern Chinese medicine granules, and Chinese medicine formula granules for the rapid growth of drugs for middle-aged and elderly people, children's medicine, antiviral drugs, and orthopedic drugs. Looking to the future, Shenwei Pharmaceutical will continue to deepen its development in the new Chinese medicine industry, continuously strengthen its professional academic marketing capabilities and precise brand management capabilities, and be the maker of modern Chinese medicine standards, the leader of modern Chinese medicine technology, and the guarantee of modern Chinese medicine quality. A demonstration of modern Chinese medicine innovation, leading modern Chinese medicine, promoting the health industry, and creating a century-old magical power.
Shenwei Pharmaceutical Group Co., Ltd.
Shenwei Pharmaceutical Group is a large comprehensive enterprise group with the new Chinese medicine industry as its main business, and is listed on the main board of the Hong Kong Stock Exchange. Its main business covers Chinese medicinal materials cultivation, Chinese medicine preparations, Chinese medicine formula granules, Chinese herbal medicines, health products, and biopharmaceuticals. The upstream, midstream and downstream industrial chains have achieved full coverage of the new Chinese medicine industry from the field to the terminal, and are one of the large pharmaceutical enterprise groups with a relatively complete layout in the big health industry. Shenwei Pharmaceutical has formed special products such as modern Chinese medicine injections, modern Chinese medicine soft capsules, modern Chinese medicine granules, and Chinese medicine formula granules for the rapid growth of drugs for middle-aged and elderly people, children's medicine, antiviral drugs, and orthopedic drugs. Looking to the future, Shenwei Pharmaceutical will continue to deepen its development in the new Chinese medicine industry, continuously strengthen its professional academic marketing capabilities and precise brand management capabilities, and be the maker of modern Chinese medicine standards, the leader of modern Chinese medicine technology, and the guarantee of modern Chinese medicine quality. A demonstration of modern Chinese medicine innovation, leading modern Chinese medicine, promoting the health industry, and creating a century-old magical power.
Guangzhou Baiyunshan Pharmaceutical Holdings Co., Ltd.
Guangzhou Baiyunshan Xingqun (Pharmaceutical) Co., Ltd. is a member of the listed company "Guangzhou Baiyunshan Pharmaceutical Group Co., Ltd." (listed in Hong Kong H shares and Shanghai A shares) controlled by Guangzhou Pharmaceutical Group. Its predecessor was founded in 1950. In 2018, the Guangzhou Xingqun Traditional Chinese Medicine Refinery, which was the first in China to carry out modernization of traditional Chinese medicine, can be traced back to Huang Xianghua Pharmaceutical Factory in 1868. After years of continuous innovation and development, it has become a large dosage form of granules, soft capsules, oral solutions, liniments, tinctures, syrup, etc., with more than 600 employees, annual sales of nearly 500 million yuan, and annual profit tax exceeding the annual profit tax. A modern pharmaceutical and health enterprise with RMB 60 million. In recent years, it has won the honors of China Customs Trusted Enterprise, National Quality Management Award, National High-tech Enterprise, National Contract-Based and Trustworthy Enterprise, and National Intellectual Property Advantage Enterprise. The company has always adhered to the corporate mission of "Health Star, Caring for the People", caring for the health of the public, promoting household medicines, fulfilling social responsibilities, pursuing excellent quality, and creating a trusted brand. The company's main representative products include: Xiasangju Granules, Ertian Oil, Pediatric Aminophen Huangnamin Granules, Anshen Bu Brain Liquid, as well as Alpha Calcium Capsules, Compound Licorice Oral Solution, Vitamin E Soft Capsules, etc. The products are sold nationwide. Exported to America, Southeast Asia and other regions. Baiyun Mountain Star Qun Xia Sangju has been trusted by consumers for many years. After nearly 40 years of large-scale and modern production, the cumulative sales have exceeded 11 billion small parcels, benefiting 11 billion people at home and abroad, and the average annual sales revenue of the product has reached 200 million yuan. Xingqun Company has always insisted on inheriting the essence and upholding the truth and innovating. While vigorously developing its main pharmaceutical business, it has actively entered the pharmaceutical and health industry. It has successively launched a series of big health products such as food, mineral water, health products, pharmaceutical cosmetics, and healthy beverages. Market recognition and welcome. The company currently has 4 national, provincial and municipal R&D platforms, including Guangdong Provincial Enterprise Technology Center, Guangdong Traditional Chinese Medicine Drop Engineering Technology Research Center, Guangzhou Municipal Enterprise Technology Center, Guangzhou Enterprise Research and Development Institution (Children). medicine direction). The company has successively introduced a number of production equipment and testing instruments with international advanced level, with fully automatic particle manufacturing and packaging equipment, soft capsule manufacturing equipment, hard capsule filling equipment, liquid infusion equipment, capsule packaging equipment and high-performance liquid chromatographs, etc. Advanced equipment. Baiyunshan Xingqun Company has a glorious historical tradition of innovation. At a time when New China is in a state of incomplete development, it pioneered the modernization of traditional Chinese medicine, started the country's traditional Chinese medicine refining agents and plant medicine purification, and pioneered the country's first suppression method to prepare soft capsules. It was the first to develop a successful granule powder, which has cultivated excellent innovative and creative genes and continuously led the development of traditional Chinese medicine culture. Looking to the future, Xingqun people are committed to building a modern enterprise with global passion and fighting spirit, with unique characteristics and distinct cultures for traditional Chinese medicine. They take it as their mission to revitalize the national pharmaceutical industry and strive to contribute to the revitalization and development of the traditional Chinese medicine health industry. .
Guangzhou Baiyunshan Pharmaceutical Holdings Co., Ltd.
Guangzhou Baiyunshan Xingqun (Pharmaceutical) Co., Ltd. is a member of the listed company "Guangzhou Baiyunshan Pharmaceutical Group Co., Ltd." (listed in Hong Kong H shares and Shanghai A shares) controlled by Guangzhou Pharmaceutical Group. Its predecessor was founded in 1950. In 2018, the Guangzhou Xingqun Traditional Chinese Medicine Refinery, which was the first in China to carry out modernization of traditional Chinese medicine, can be traced back to Huang Xianghua Pharmaceutical Factory in 1868. After years of continuous innovation and development, it has become a large dosage form of granules, soft capsules, oral solutions, liniments, tinctures, syrup, etc., with more than 600 employees, annual sales of nearly 500 million yuan, and annual profit tax exceeding the annual profit tax. A modern pharmaceutical and health enterprise with RMB 60 million. In recent years, it has won the honors of China Customs Trusted Enterprise, National Quality Management Award, National High-tech Enterprise, National Contract-Based and Trustworthy Enterprise, and National Intellectual Property Advantage Enterprise. The company has always adhered to the corporate mission of "Health Star, Caring for the People", caring for the health of the public, promoting household medicines, fulfilling social responsibilities, pursuing excellent quality, and creating a trusted brand. The company's main representative products include: Xiasangju Granules, Ertian Oil, Pediatric Aminophen Huangnamin Granules, Anshen Bu Brain Liquid, as well as Alpha Calcium Capsules, Compound Licorice Oral Solution, Vitamin E Soft Capsules, etc. The products are sold nationwide. Exported to America, Southeast Asia and other regions. Baiyun Mountain Star Qun Xia Sangju has been trusted by consumers for many years. After nearly 40 years of large-scale and modern production, the cumulative sales have exceeded 11 billion small parcels, benefiting 11 billion people at home and abroad, and the average annual sales revenue of the product has reached 200 million yuan. Xingqun Company has always insisted on inheriting the essence and upholding the truth and innovating. While vigorously developing its main pharmaceutical business, it has actively entered the pharmaceutical and health industry. It has successively launched a series of big health products such as food, mineral water, health products, pharmaceutical cosmetics, and healthy beverages. Market recognition and welcome. The company currently has 4 national, provincial and municipal R&D platforms, including Guangdong Provincial Enterprise Technology Center, Guangdong Traditional Chinese Medicine Drop Engineering Technology Research Center, Guangzhou Municipal Enterprise Technology Center, Guangzhou Enterprise Research and Development Institution (Children). medicine direction). The company has successively introduced a number of production equipment and testing instruments with international advanced level, with fully automatic particle manufacturing and packaging equipment, soft capsule manufacturing equipment, hard capsule filling equipment, liquid infusion equipment, capsule packaging equipment and high-performance liquid chromatographs, etc. Advanced equipment. Baiyunshan Xingqun Company has a glorious historical tradition of innovation. At a time when New China is in a state of incomplete development, it pioneered the modernization of traditional Chinese medicine, started the country's traditional Chinese medicine refining agents and plant medicine purification, and pioneered the country's first suppression method to prepare soft capsules. It was the first to develop a successful granule powder, which has cultivated excellent innovative and creative genes and continuously led the development of traditional Chinese medicine culture. Looking to the future, Xingqun people are committed to building a modern enterprise with global passion and fighting spirit, with unique characteristics and distinct cultures for traditional Chinese medicine. They take it as their mission to revitalize the national pharmaceutical industry and strive to contribute to the revitalization and development of the traditional Chinese medicine health industry. .
Sichuan Fengchun Pharmaceutical Co., Ltd.
Sichuan Fengchun Pharmaceutical Co., Ltd. (abbreviated as Fengchun/Fengchun Pharmaceutical) was founded in 1973 and completed its strategic restructuring in 2000 after the restructuring of the former Zhongjiang Pharmaceutical Factory. Now, a modern private enterprise has been formed that integrates pharmaceutical research, industrial production, pharmaceutical sales, agricultural breeding, big health industry, and project investment. As a long-standing pharmaceutical company in Kawachi, it has been devoted to inheriting the innovative development of traditional Chinese medicine and modern medicine. At present, it has 4 GMP production factories (including well-known subsidiaries such as Jiuzhaigou Natural Pharmaceutical and Sichuan Shenghe Pharmaceutical); more than 20 breeding companies; more than 5,000 employees; the company, wholly-owned subsidiaries and shareholders have assets of nearly 30 RMB 100 million; more than 1,500 mu of industrial land, with an industrial construction area of more than 330,000 square meters; more than 230,000 mu of GAP planting land, forestry and aquaculture land. In 2014, Fengchun acquired Jiuzhaigou Natural Pharmaceutical Co., Ltd. and its four wholly-owned subsidiaries; in early 2020, Fengchun Holdings Sichuan Shenghe Pharmaceutical Co., Ltd. and its two wholly-owned subsidiaries: 2021 Sichuan Fengchuntang Chinese Medicine Decoction Co., Ltd. was established in 2022 and passed the GMP certification, committed to creating Chinese medicine fine decoctions. At this point, Fengchun has taken solid steps in building a traditional Chinese and Western medicine industry with domestic first-class R&D capabilities, extremely large production scale and characteristics, as well as the Qiang and Tibetan ethnic pharmaceutical industries. At present, its pharmaceutical companies have 114 invention patents and 403 drug production approval documents. In order to sustainable protection and utilization of scarce traditional Chinese medicine resources, its Sichuan Fengchun Musk Industry Group has been established and approved 13 artificially bred forest musk and horse musk subsidiaries, and another 7 are under construction. Jiuzhaigou Natural Pharmaceutical Co., Ltd., a subsidiary, is one of more than 10 pharmaceutical companies approved to use natural musk in China recently, and is also a pharmaceutical company approved to use natural musk as a drug product in China.
Sichuan Fengchun Pharmaceutical Co., Ltd.
Sichuan Fengchun Pharmaceutical Co., Ltd. (abbreviated as Fengchun/Fengchun Pharmaceutical) was founded in 1973 and completed its strategic restructuring in 2000 after the restructuring of the former Zhongjiang Pharmaceutical Factory. Now, a modern private enterprise has been formed that integrates pharmaceutical research, industrial production, pharmaceutical sales, agricultural breeding, big health industry, and project investment. As a long-standing pharmaceutical company in Kawachi, it has been devoted to inheriting the innovative development of traditional Chinese medicine and modern medicine. At present, it has 4 GMP production factories (including well-known subsidiaries such as Jiuzhaigou Natural Pharmaceutical and Sichuan Shenghe Pharmaceutical); more than 20 breeding companies; more than 5,000 employees; the company, wholly-owned subsidiaries and shareholders have assets of nearly 30 RMB 100 million; more than 1,500 mu of industrial land, with an industrial construction area of more than 330,000 square meters; more than 230,000 mu of GAP planting land, forestry and aquaculture land. In 2014, Fengchun acquired Jiuzhaigou Natural Pharmaceutical Co., Ltd. and its four wholly-owned subsidiaries; in early 2020, Fengchun Holdings Sichuan Shenghe Pharmaceutical Co., Ltd. and its two wholly-owned subsidiaries: 2021 Sichuan Fengchuntang Chinese Medicine Decoction Co., Ltd. was established in 2022 and passed the GMP certification, committed to creating Chinese medicine fine decoctions. At this point, Fengchun has taken solid steps in building a traditional Chinese and Western medicine industry with domestic first-class R&D capabilities, extremely large production scale and characteristics, as well as the Qiang and Tibetan ethnic pharmaceutical industries. At present, its pharmaceutical companies have 114 invention patents and 403 drug production approval documents. In order to sustainable protection and utilization of scarce traditional Chinese medicine resources, its Sichuan Fengchun Musk Industry Group has been established and approved 13 artificially bred forest musk and horse musk subsidiaries, and another 7 are under construction. Jiuzhaigou Natural Pharmaceutical Co., Ltd., a subsidiary, is one of more than 10 pharmaceutical companies approved to use natural musk in China recently, and is also a pharmaceutical company approved to use natural musk as a drug product in China.
Chongqing Taiji Industry (Group) Co., Ltd.
Taiji Group Co., Ltd. (hereinafter referred to as "Taiji Group", stock code: 600129) was established in 1972 and completed its strategic restructuring in 2021, becoming a holding company of China Pharmaceutical Group Co., Ltd., the "Fortune 500" company. The company mainly focuses on intelligent manufacturing of modern Chinese medicine and supplemented by specialty chemical drugs. As an important part of the modern Chinese medicine sector of Sinopharm Group, it is committed to inheriting and innovating traditional Chinese medicine and developing modern medicine. It has 13 pharmaceutical factories and more than 20 pharmaceutical businesses. The company has more than 3,000 chain pharmacies with Sichuan and Chongqing as its main base, covering pharmaceutical research and development, pharmaceutical production, pharmaceutical commerce, Chinese medicinal materials resources and other fields, with 13,000 employees. In 1998, Taiji Group cooperated with many domestic and foreign institutions to establish a national postdoctoral workstation; in 1999, Taiji Group Technology Center was recognized as a National Enterprise Technology Center. In recent years, it has undertaken nearly 40 major special projects such as the Ministry of Science and Technology, the National Development and Reform Commission, and the Ministry of Industry and Information Technology, and more than 50 provincial projects. The company has successfully developed more than 40 new drugs, won more than 30 national new drug certificates, and won three Chinese patent gold medals. It has 300 valid authorized patents, a total of 1,240 drug approval documents, including 690 Chinese medicine varieties, 550 chemical medicine varieties, 739 medical insurance varieties, and 369 basic drugs. The company's products cover six major therapeutic areas, mainly including digestive system and metabolic drugs represented by Huoxiang Zhengqi Oral Liquid, Tailuo, etc., respiratory system drugs represented by acute syrup, and cardiovascular drugs represented by Salvia miltiorrhiza oral Liquid. , anti-infective drugs represented by Yibao Shiling, nervous system drugs represented by Tongtian Oral Liquid and Mefikang, anti-tumor and immunomodulatory drugs represented by paclitaxel, Bushen Yishou Capsules, etc., and Big Health Health products. The company's products have a high market share, and its brand and quality have won the recognition and trust of the people. Taiji Group will adhere to the corporate philosophy of "caring for life and caring for health", with the original mission of "Chinese Medicine Conservation in China, Taiji Helps the people", follow the goal positioning of "making the main business of medical and health stronger, better and bigger", and produce new sources, We will strive for excellence, continuously promote the modernization of traditional Chinese medicine, strive to build a world-class traditional Chinese medicine enterprise, promote traditional Chinese medicine to the world, and contribute the power of Chinese medicine Tai Chi to build a healthy China and realize the Chinese dream of the great rejuvenation of the Chinese nation.
Chongqing Taiji Industry (Group) Co., Ltd.
Taiji Group Co., Ltd. (hereinafter referred to as "Taiji Group", stock code: 600129) was established in 1972 and completed its strategic restructuring in 2021, becoming a holding company of China Pharmaceutical Group Co., Ltd., the "Fortune 500" company. The company mainly focuses on intelligent manufacturing of modern Chinese medicine and supplemented by specialty chemical drugs. As an important part of the modern Chinese medicine sector of Sinopharm Group, it is committed to inheriting and innovating traditional Chinese medicine and developing modern medicine. It has 13 pharmaceutical factories and more than 20 pharmaceutical businesses. The company has more than 3,000 chain pharmacies with Sichuan and Chongqing as its main base, covering pharmaceutical research and development, pharmaceutical production, pharmaceutical commerce, Chinese medicinal materials resources and other fields, with 13,000 employees. In 1998, Taiji Group cooperated with many domestic and foreign institutions to establish a national postdoctoral workstation; in 1999, Taiji Group Technology Center was recognized as a National Enterprise Technology Center. In recent years, it has undertaken nearly 40 major special projects such as the Ministry of Science and Technology, the National Development and Reform Commission, and the Ministry of Industry and Information Technology, and more than 50 provincial projects. The company has successfully developed more than 40 new drugs, won more than 30 national new drug certificates, and won three Chinese patent gold medals. It has 300 valid authorized patents, a total of 1,240 drug approval documents, including 690 Chinese medicine varieties, 550 chemical medicine varieties, 739 medical insurance varieties, and 369 basic drugs. The company's products cover six major therapeutic areas, mainly including digestive system and metabolic drugs represented by Huoxiang Zhengqi Oral Liquid, Tailuo, etc., respiratory system drugs represented by acute syrup, and cardiovascular drugs represented by Salvia miltiorrhiza oral Liquid. , anti-infective drugs represented by Yibao Shiling, nervous system drugs represented by Tongtian Oral Liquid and Mefikang, anti-tumor and immunomodulatory drugs represented by paclitaxel, Bushen Yishou Capsules, etc., and Big Health Health products. The company's products have a high market share, and its brand and quality have won the recognition and trust of the people. Taiji Group will adhere to the corporate philosophy of "caring for life and caring for health", with the original mission of "Chinese Medicine Conservation in China, Taiji Helps the people", follow the goal positioning of "making the main business of medical and health stronger, better and bigger", and produce new sources, We will strive for excellence, continuously promote the modernization of traditional Chinese medicine, strive to build a world-class traditional Chinese medicine enterprise, promote traditional Chinese medicine to the world, and contribute the power of Chinese medicine Tai Chi to build a healthy China and realize the Chinese dream of the great rejuvenation of the Chinese nation.
Guangzhou Xiangxue Pharmaceutical Co., Ltd.
Guangzhou Xiangxue Pharmaceutical Co., Ltd. was established in 1997 and was listed on the Shenzhen Stock Exchange GEM in 2010 (stock code: 300147). The company regards the development of traditional Chinese medicine and the realization of traditional Chinese medicine modernization as its long-term development strategy. It has now become a leading Chinese medicine modernization enterprise and high-tech enterprise with independent intellectual property rights, independent brands and independent innovation capabilities, focusing on new Chinese herbal medicines, Chinese patent medicines, functional health products, The big health industry in the fields of biomedical engineering, life science research, etc. has successively established more than 60 subsidiaries in Guangdong, Beijing, Shanxi, Sichuan, Chongqing, Anhui, Yunnan and Ningxia, and invested in the construction of large-scale GMP production bases and GAPs. Medicinal materials planting bases will create a complete industrial chain of traditional Chinese medicine resource development, new drug research and development and creation, advanced traditional Chinese medicine manufacturing, and modern logistics and distribution, and form integrated innovation of the entire industrial chain.
Guangzhou Xiangxue Pharmaceutical Co., Ltd.
Guangzhou Xiangxue Pharmaceutical Co., Ltd. was established in 1997 and was listed on the Shenzhen Stock Exchange GEM in 2010 (stock code: 300147). The company regards the development of traditional Chinese medicine and the realization of traditional Chinese medicine modernization as its long-term development strategy. It has now become a leading Chinese medicine modernization enterprise and high-tech enterprise with independent intellectual property rights, independent brands and independent innovation capabilities, focusing on new Chinese herbal medicines, Chinese patent medicines, functional health products, The big health industry in the fields of biomedical engineering, life science research, etc. has successively established more than 60 subsidiaries in Guangdong, Beijing, Shanxi, Sichuan, Chongqing, Anhui, Yunnan and Ningxia, and invested in the construction of large-scale GMP production bases and GAPs. Medicinal materials planting bases will create a complete industrial chain of traditional Chinese medicine resource development, new drug research and development and creation, advanced traditional Chinese medicine manufacturing, and modern logistics and distribution, and form integrated innovation of the entire industrial chain.
Livzon Pharmaceutical Group Inc.
Lizhu Pharmaceutical Group Co., Ltd. was founded in January 1985 with a registered capital of 935 million yuan. It is a comprehensive pharmaceutical group company integrating pharmaceutical research and development, production and sales. It currently has more than 8,000 employees and is an A+H-share listed company. In 2021, the company's operating income was 12.06 billion yuan, net profit was 1.78 billion yuan, and R&D investment was 1.52 billion yuan. Lizhu has made continuous breakthroughs in the fields of raw materials, chemical drugs, traditional Chinese medicines, biological drugs, in vitro diagnostic reagents, etc., and its products are distributed in digestive, cardiovascular, reproductive endocrine, mental/nervous fields. The company continues to focus on the main business of innovative drugs and high-barrier complex preparations, and has launched blockbuster products such as leuprolide and esprazole, achieving large-scale growth in the fields of digestive and reproductive. Lizhu has formed a prescription drug marketing network that radiates across the country and is rapidly promoting the construction of a global sales platform. Through professional academic promotion and high-quality products with accurate efficacy, a good communication channel has been established with hospitals and patients. Lizon's development is inseparable from the continuous joining of outstanding talents and the continuous high-growth R&D investment. The company has built a comprehensive network of scientists and continuously recruited talents around the world. The R&D team has hundreds of doctoral and high-end R&D personnel. In the future, Lizon will continue to focus on the field of life and health, continuously improve the quality of life of patients, continue to shoulder social responsibilities and mission responsibilities, actively participate in public welfare undertakings, and accelerate the company's pace towards globalization.
Livzon Pharmaceutical Group Inc.
Lizhu Pharmaceutical Group Co., Ltd. was founded in January 1985 with a registered capital of 935 million yuan. It is a comprehensive pharmaceutical group company integrating pharmaceutical research and development, production and sales. It currently has more than 8,000 employees and is an A+H-share listed company. In 2021, the company's operating income was 12.06 billion yuan, net profit was 1.78 billion yuan, and R&D investment was 1.52 billion yuan. Lizhu has made continuous breakthroughs in the fields of raw materials, chemical drugs, traditional Chinese medicines, biological drugs, in vitro diagnostic reagents, etc., and its products are distributed in digestive, cardiovascular, reproductive endocrine, mental/nervous fields. The company continues to focus on the main business of innovative drugs and high-barrier complex preparations, and has launched blockbuster products such as leuprolide and esprazole, achieving large-scale growth in the fields of digestive and reproductive. Lizhu has formed a prescription drug marketing network that radiates across the country and is rapidly promoting the construction of a global sales platform. Through professional academic promotion and high-quality products with accurate efficacy, a good communication channel has been established with hospitals and patients. Lizon's development is inseparable from the continuous joining of outstanding talents and the continuous high-growth R&D investment. The company has built a comprehensive network of scientists and continuously recruited talents around the world. The R&D team has hundreds of doctoral and high-end R&D personnel. In the future, Lizon will continue to focus on the field of life and health, continuously improve the quality of life of patients, continue to shoulder social responsibilities and mission responsibilities, actively participate in public welfare undertakings, and accelerate the company's pace towards globalization.
Sichuan Yike Pharmaceutical Co., Ltd.
Sichuan Yike Pharmaceutical Co., Ltd. is a high-tech international enterprise with the big health industry as its main line, the biopharmaceutical industry as its core, and the health industry and medical rehabilitation, health care and health management as its wings. There are more than ten subsidiaries, and have established academician and expert workstations, postdoctoral innovation practice bases and enterprise R&D centers. The group has China's advanced Chinese medicine extraction and preparation production capabilities, and has the ability to produce varieties such as medicine and food, health food, and health tablets. The group has formed a modern pharmaceutical industry chain that integrates all aspects of drug research and development, medicinal material planting, Chinese medicine extraction, preparation production and marketing, and has developed and cultivated a group of traditional Chinese and Western medicine products with accurate efficacy and high market reputation, among which the most Representative Ammonia Huangmin Capsules, Gake Compound Aminophen Alkylamine Capsules, Aminophen Namin Granules, Pediatric Aminophen Huangnamin Granules, Amoxicillin Capsules, Multi-enzyme Tablets, Huoxiang Zhengqi Water, Compound Salvia Squid Sinensis Tablets, A series of Chinese and Western medicines such as isatis root granules, Jingxueguanxin granules, Tongmai granules, Tongxuanlifei granules, etc. are highly recognized by consumers. Looking to the future, the Group will vigorously integrate resources and promote the strategy of strengthening talents and managing innovation under the guidance of "sophisticated, meticulous and strict learning, understanding the changes of the situation, specializing in new ideas, and inheriting culture". Medicine is our responsibility, with a scientific, rigorous and responsible attitude, we wholeheartedly create healthy life for the people, and strive to strive for the goals of China's advanced pharmaceutical companies.
Sichuan Yike Pharmaceutical Co., Ltd.
Sichuan Yike Pharmaceutical Co., Ltd. is a high-tech international enterprise with the big health industry as its main line, the biopharmaceutical industry as its core, and the health industry and medical rehabilitation, health care and health management as its wings. There are more than ten subsidiaries, and have established academician and expert workstations, postdoctoral innovation practice bases and enterprise R&D centers. The group has China's advanced Chinese medicine extraction and preparation production capabilities, and has the ability to produce varieties such as medicine and food, health food, and health tablets. The group has formed a modern pharmaceutical industry chain that integrates all aspects of drug research and development, medicinal material planting, Chinese medicine extraction, preparation production and marketing, and has developed and cultivated a group of traditional Chinese and Western medicine products with accurate efficacy and high market reputation, among which the most Representative Ammonia Huangmin Capsules, Gake Compound Aminophen Alkylamine Capsules, Aminophen Namin Granules, Pediatric Aminophen Huangnamin Granules, Amoxicillin Capsules, Multi-enzyme Tablets, Huoxiang Zhengqi Water, Compound Salvia Squid Sinensis Tablets, A series of Chinese and Western medicines such as isatis root granules, Jingxueguanxin granules, Tongmai granules, Tongxuanlifei granules, etc. are highly recognized by consumers. Looking to the future, the Group will vigorously integrate resources and promote the strategy of strengthening talents and managing innovation under the guidance of "sophisticated, meticulous and strict learning, understanding the changes of the situation, specializing in new ideas, and inheriting culture". Medicine is our responsibility, with a scientific, rigorous and responsible attitude, we wholeheartedly create healthy life for the people, and strive to strive for the goals of China's advanced pharmaceutical companies.
Tazo is known for its innovative and exotic tea blends, offering a jasmine tea that combines the floral notes of jasmine with the richness of green tea.
Tazo Tea Company
Tazo is known for its innovative and exotic tea blends, offering a jasmine tea that combines the floral notes of jasmine with the richness of green tea.
The Republic of Tea offers a variety of artisanal teas, including a jasmine tea that is carefully crafted to provide a soothing and aromatic experience.
The Republic of Tea
The Republic of Tea offers a variety of artisanal teas, including a jasmine tea that is carefully crafted to provide a soothing and aromatic experience.
Harney & Sons is a premium tea company that specializes in blending and packaging fine teas, including their exquisite jasmine tea, which is celebrated for its smooth and fragrant profile.
Harney & Sons Fine Teas
Harney & Sons is a premium tea company that specializes in blending and packaging fine teas, including their exquisite jasmine tea, which is celebrated for its smooth and fragrant profile.
Pokka is a Japanese beverage company offering a wide range of drinks, including plum-based beverages, with a focus on convenience and taste.
Pokka Corporation
Pokka is a Japanese beverage company offering a wide range of drinks, including plum-based beverages, with a focus on convenience and taste.
Known for its herbal teas and wellness products, Yogi Tea also offers ingredients for traditional health soups.
Yogi Tea GmbH
Known for its herbal teas and wellness products, Yogi Tea also offers ingredients for traditional health soups.
Traditional Medicinals, Inc.
Traditional Medicinals is a well-known brand for herbal teas and remedies, including their autumn pear syrup.
Traditional Medicinals, Inc.
Traditional Medicinals is a well-known brand for herbal teas and remedies, including their autumn pear syrup.
Beijing Tong Ren Tang Group
Tong Ren Tang is a centuries-old brand known for its traditional Chinese medicine, including its effective autumn pear syrup.
Beijing Tong Ren Tang Group
Tong Ren Tang is a centuries-old brand known for its traditional Chinese medicine, including its effective autumn pear syrup.
Shanghai Associated British Foods Beverages Co., Ltd.
TWININGS is a brand founded by British Thomas Twining. In 1706 AD, Mr. Kwaning opened a cafe in the UK under the name of "Thomas", which is the predecessor of TWININGS. Since its birth in 1706, Sichuan-Ning tea has led a new trend in tea drinking culture. In the eyes of tea culture all over the world, Chuanning tea is the representative of drinking tea. In 837, Queen Victoria of the British royal family issued the first "Royal Appointment Letter", and Sichuan-Ning Tea was designated as the royal tea, and this honor has been passed down to this day. The royal family members, including the Queen herself, the Queen's mother and Prince Charles, all highly praised Chuanning Tea. In 1717, Thomas opened a black tea specialty store - "Golden Lion", which was highly appreciated and favored by royal families such as Queen Victoria, George V, and Edward VII. What's more fortunate is that Chuanning Tea won the "Queen Medal" for the second time in 1972 and 1977, becoming the first tea company to be approved for export, thus successfully entering the world tea culture market. London& Today, Sichuan-Ning Tea has become popular in more than 100 countries around the world. Sichuan Ning tea not only has traditional black and green tea series, but also fruit tea, flower tea and ice tea series, especially suitable for the tastes of the younger generation. These trendy tea collections also reflect the trend of people around the world in pursuing healthier and more postures.
Shanghai Associated British Foods Beverages Co., Ltd.
TWININGS is a brand founded by British Thomas Twining. In 1706 AD, Mr. Kwaning opened a cafe in the UK under the name of "Thomas", which is the predecessor of TWININGS. Since its birth in 1706, Sichuan-Ning tea has led a new trend in tea drinking culture. In the eyes of tea culture all over the world, Chuanning tea is the representative of drinking tea. In 837, Queen Victoria of the British royal family issued the first "Royal Appointment Letter", and Sichuan-Ning Tea was designated as the royal tea, and this honor has been passed down to this day. The royal family members, including the Queen herself, the Queen's mother and Prince Charles, all highly praised Chuanning Tea. In 1717, Thomas opened a black tea specialty store - "Golden Lion", which was highly appreciated and favored by royal families such as Queen Victoria, George V, and Edward VII. What's more fortunate is that Chuanning Tea won the "Queen Medal" for the second time in 1972 and 1977, becoming the first tea company to be approved for export, thus successfully entering the world tea culture market. London& Today, Sichuan-Ning Tea has become popular in more than 100 countries around the world. Sichuan Ning tea not only has traditional black and green tea series, but also fruit tea, flower tea and ice tea series, especially suitable for the tastes of the younger generation. These trendy tea collections also reflect the trend of people around the world in pursuing healthier and more postures.
Bigelow Tea provides a variety of herbal teas, including chrysanthemum blends, known for their comforting and soothing properties.
R.C. Bigelow, Inc.
Bigelow Tea provides a variety of herbal teas, including chrysanthemum blends, known for their comforting and soothing properties.
Eu Yan Sang Trading (Guangdong) Co., Ltd.
In 1873, Yu Guang left his hometown and came to Malaya from Foshan, Guangdong, China to seek development. He later settled in Wubian, a small tin mine town in Perak. At that time, opium was flooded and local tin miners used opium to escape hard work and harsh environment. Yu Guang was determined to use traditional Chinese medicine to rescue miners and opened his first pharmacy in Wubian in 1879. Yu Guang named the medicine shop "Rensheng". "Benevolence" represents "benevolence and kindness"; life means "life and sentient beings". "Rensheng" means "benevolence and sentient beings". After Yu Guang's only son Yu Dongxuan inherited his father's business, he quickly made a name for himself in Singapore and Malaya's business circles with his keen judgment and unique vision. He not only carried forward the traditional Chinese medicine business, but also became a leader in the tin ore and rubber planting industry at that time. Later, Yu Dongxuan further expanded Yu Renshen's business and extended his sales network to Hong Kong and China. While actively expanding business, Yu Dongxuan practices the spirit of "benevolent sentient beings" in every business base. Afterwards, Yu Rensheng adhered to the belief advocated by his predecessors and developed the former town pharmacy shops to today's international traditional Chinese medicine enterprises. The company carried forward the fine traditions and was committed to caring for all living beings while promoting the development of traditional Chinese medicine. Yu Rensheng aims to become a trustworthy leading company in the field of comprehensive health care and health care, while continuing to preserve the unique foundation of traditional Chinese medicine. Yu Rensheng International Group is listed on the Singapore Stock Exchange and is also one of the relatively large-scale traditional Chinese medicine health care companies outside mainland China. It is recognized as a leader in the traditional Chinese medicine health care industry. When manufacturing and retailing traditional Chinese medicine and health care products, Yu Rensheng is committed to combining excellent pharmaceutical traditions with modern scientific research and continuous improvement in product quality and research and development. Today, Yu Rensheng provides products and services through retail stores, traditional Chinese medicine clinics and life concept stores, integrating traditional Chinese medicine into mainstream medical services and modern life models.
Eu Yan Sang Trading (Guangdong) Co., Ltd.
In 1873, Yu Guang left his hometown and came to Malaya from Foshan, Guangdong, China to seek development. He later settled in Wubian, a small tin mine town in Perak. At that time, opium was flooded and local tin miners used opium to escape hard work and harsh environment. Yu Guang was determined to use traditional Chinese medicine to rescue miners and opened his first pharmacy in Wubian in 1879. Yu Guang named the medicine shop "Rensheng". "Benevolence" represents "benevolence and kindness"; life means "life and sentient beings". "Rensheng" means "benevolence and sentient beings". After Yu Guang's only son Yu Dongxuan inherited his father's business, he quickly made a name for himself in Singapore and Malaya's business circles with his keen judgment and unique vision. He not only carried forward the traditional Chinese medicine business, but also became a leader in the tin ore and rubber planting industry at that time. Later, Yu Dongxuan further expanded Yu Renshen's business and extended his sales network to Hong Kong and China. While actively expanding business, Yu Dongxuan practices the spirit of "benevolent sentient beings" in every business base. Afterwards, Yu Rensheng adhered to the belief advocated by his predecessors and developed the former town pharmacy shops to today's international traditional Chinese medicine enterprises. The company carried forward the fine traditions and was committed to caring for all living beings while promoting the development of traditional Chinese medicine. Yu Rensheng aims to become a trustworthy leading company in the field of comprehensive health care and health care, while continuing to preserve the unique foundation of traditional Chinese medicine. Yu Rensheng International Group is listed on the Singapore Stock Exchange and is also one of the relatively large-scale traditional Chinese medicine health care companies outside mainland China. It is recognized as a leader in the traditional Chinese medicine health care industry. When manufacturing and retailing traditional Chinese medicine and health care products, Yu Rensheng is committed to combining excellent pharmaceutical traditions with modern scientific research and continuous improvement in product quality and research and development. Today, Yu Rensheng provides products and services through retail stores, traditional Chinese medicine clinics and life concept stores, integrating traditional Chinese medicine into mainstream medical services and modern life models.
Lipton (Shanghai) Plant Products Co., Ltd.
"Lipton" is the world's largest tea brand. Lipton’s purpose is to enjoy light, vitality and natural beauty. Toms Lipton is the founder of this brand. In 1890, he officially launched Lipton Black Tea in the UK and used the advertising slogan "Direct from tea garden to the tea pot". In 1892, Lipton began a globalization movement, first setting up factories in the United States, then opening branches in India, and entering the Far East market. In 1898, Lipton was awarded the title of "King of Black Tea in the World". In 1992, Lipton entered China, a country with a long history of drinking tea and a large number of people drinking tea. Lipton’s iconic yellow-label black tea is available in more than 100 countries, and Lipton continues to select good tea from high-quality tea gardens around the world. Lipton combines passion and expertise to provide delicious black tea flavor and balanced flavor with aromatic flavors.
Lipton (Shanghai) Plant Products Co., Ltd.
"Lipton" is the world's largest tea brand. Lipton’s purpose is to enjoy light, vitality and natural beauty. Toms Lipton is the founder of this brand. In 1890, he officially launched Lipton Black Tea in the UK and used the advertising slogan "Direct from tea garden to the tea pot". In 1892, Lipton began a globalization movement, first setting up factories in the United States, then opening branches in India, and entering the Far East market. In 1898, Lipton was awarded the title of "King of Black Tea in the World". In 1992, Lipton entered China, a country with a long history of drinking tea and a large number of people drinking tea. Lipton’s iconic yellow-label black tea is available in more than 100 countries, and Lipton continues to select good tea from high-quality tea gardens around the world. Lipton combines passion and expertise to provide delicious black tea flavor and balanced flavor with aromatic flavors.
